Resultado da Busca
24 de mai. de 2024 · Introduction. Colorectal cancer (CRC) is the third most commonly diagnosed cancer and the second leading cause of cancer death, accounting for nearly 9.4% of total cancer deaths. 1 CRC can develop through at least three distinct pathological pathways, including the microsatellite instability (MSI), chromosomal instability, and CpG island methylator phenotype pathways. 2 CRC harboring MSI is ...
29 de mai. de 2024 · e15533 Background: Peritoneal metastases occur in approximately 10% of all colorectal cancer (CRC) patients, which are associated with significant morbidity and worse clinical outcome. To date, the evolutionary pattern and molecular mechanisms of peritoneal metastases remains largely unknown, which provided little insights into the prevention and treatment of this subgroup of CRC patients ...
14 de mai. de 2024 · 11. Flechon A, Pouessel D, Ferlay C, Perol D, Beuzeboc P, Gravis G, et al. Phase ii study of carboplatin and etoposide in patients with anaplastic progressive metastatic castration-resistant prostate cancer (Mcrpc) with or without neuroendocrine differentiation: results of the french genito-urinary tumor group (Getug) P01 trial. Ann Oncol.
10 de mai. de 2024 · Jonathan M. Loree, Emma Titmuss, James T. Topham, Hagen F. Kennecke, Harriet Feilotter, Shakeel Virk, Young S. Lee, Kimberly Banks, Katie Quinn, Aly Karsan, Daniel J. Renouf, Derek J. Jonker, Dongsheng Tu, Chris J. O'Callaghan, Eric X. Chen; Plasma versus tissue tumor mutational burden as biomarkers of durvalumab plus tremelimumab response in patients with metastatic colorectal cancer in the ...
29 de mai. de 2024 · e15566 Background: Defining the impact of KRAS mutation status on outcomes to standard of care treatments in metastatic colorectal cancer (mCRC) is of increasing clinical relevance. We interrogated a large real-world genomic database to further explore the association between KRAS mutations and benefit to trifluridine-tipiracil (FTD-TPI) in patients with mCRC. Methods: 19,364 patients with ...
11 de mai. de 2024 · Patients with colorectal cancer (CRC) often exhibit changes in body composition (BC) which are associated with poorer clinical outcomes. Many studies group colon and rectal cancers together ...
27 de mai. de 2024 · Worldwide "Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market" Research Report 2024 is spread across 92+ Pages and gives important information on Size, Share, Trends, and ...
